Ophthalmic and microsurgery device maker Carl Zeiss Meditec AG is investing in regenerative medicine startup Precise Bio Ltd. to jointly develop 4D bio-fabricated corneal transplants for diseases that require endothelial keratoplasty and natural lenticule transplants. Under the terms of the agreement, Carl Zeiss Meditec will lead a series B financing round in Precise Bio and fund development of two cornea transplant products.

Microport Neurotech Ltd.’s shares started at HK$24.7 (US$3.15) per share, fell 0.162% and closed at HK$24.60 apiece on its first day of trading of July 15, 2022.

Investors are backing neurostimulation device company Stimdia Medical Inc. with $16 million, in the first tranche of a series B offering expected to total $30 million. The Minneapolis-based company is developing a device that stimulates the phrenic nerves in a patient’s neck to exercise the diaphragm during mechanical ventilation and minimize ventilation-induced diaphragmatic dysfunction (VIDD).

Controlling the epigenetics of a patient, figuring out what genes are expressed and understanding their level of expression, is at the center of Epic Bio, a new company founded by Stanley Qi, co-inventor on the CRISPR patent held by the University of California.

Xilis Inc. added $19 million to its series A financing round, bringing the total amount raised to over $89 million. FPV Ventures led the extension, with participation from Alexandria Venture Investments and EQT Life Sciences, Mubadala Capital Management, Pear Ventures, GV, the Duke Angel Network, Catalio Capital Management, Two Sigma Ventures, Felicis Ventures and Alix Ventures.